

- Title** Enercel Homeopathic Medicine for Patient with Infectious Diseases and Motor Neuron Disease
- Agency** HTA Malaysia, Health Technology Assessment Section, Medical Development Division, Ministry of Health Malaysia
Level 4, Block E1, Parcel E, Presint 1,
Federal Government Administrative Center, 62590 Putrajaya, Malaysia
Tel: +603 88831229, Fax: +603 88831230; htamalaysia@moh.gov.my, www.moh.gov.my
- Reference** Technology Review Report – 001/2014, online:
http://www.moh.gov.my/index.php/database_stores/store_view_page/30/234

Aim

The objective of this technology review was to assess the safety, efficacy/effectiveness and cost effectiveness of Enercel® for the treatment of infectious diseases (such as TB, HIV, diarrhoea and allergic disease of the upper respiratory tract) and motor neuron disease (such as amyotrophic lateral sclerosis).

Conclusions and results

There was one published literature on Enercel® (a case series) included in this technology review. In addition, there were five unpublished articles (three non-randomised controlled trials and two cross sectional study).

There was limited and low level evidence to suggest that Enercel® or Enerpuncture™ may be safe and effective to be used in the treatment of people with infectious diseases and motor neuron disease. The methodology of five unpublished articles were not clear, hence the quality of those studies cannot be assessed. In addition, there was no published literature evidence on the safety and cost-effectiveness. One unpublished articles reported no adverse events on the use of Enercel® for the treatment of multi-drug resistant TB patients. Higher quality studies are required to provide more evidence on the efficacy/effectiveness, safety and cost-effectiveness of Enercel®.

Recommendations (if any)

Enercel® is recommended for research purpose to provide more high quality evidence on effectiveness and safety.

Methods

Electronic databases were searched through the MEDLINE(R) In-process and other Non-Indexed Citations and Ovid MEDLINE(R) 1948 to present, EBM Reviews - Health Technology Assessment – 1st Quarter 2014, EBM Reviews- Database of Abstracts of Review of Effects – 4th Quarter 2013, EBM Reviews-Cochrane database of Systematic Reviews – 2005 until December 2013, EBM Reviews – NHS Economic Evaluation Database – 1st Quarter 2014 and Embase 1996 to 2014 Week 3. Other websites; INAHTA, U.S. FDA and general databases such as Google. In addition, a cross-referencing of the articles retrieved was also carried out accordingly to the topic. Relevant articles were critically appraised and evidence graded using US/Canadian Preventive Services Task Force.

Further research/reviews required

More evidences are required prior it is to be determined.

Written by

Asmirah Md Redzuan, MaHTAS, Malaysia